This inventor holds 2 USPTO granted patents. Top assignee: Cetus Corporation. Active years: 1989-1990.
Company Filing History:
Years Active: 1989-1990
Title: Brian Issell: Innovator in Immunotoxin Research
Introduction
Brian Issell is a notable inventor based in Moraga, CA (US). He has made significant contributions to the field of immunotoxin research, particularly in the treatment of cancers such as ovarian and breast cancer. With a total of 2 patents, Issell's work has the potential to impact therapeutic strategies in oncology.
Latest Patents
Issell's latest patents include innovative compositions that enhance anti-tumor activity in humans. One of his patents focuses on the "Composition of immunotoxins with interleukin-2." This invention describes a method where a pharmacologically effective amount of mammalian IL-2 is administered alongside an immunotoxin that selectively binds to human tumor cells. The separate administration of IL-2 and the immunotoxin is designed to improve treatment outcomes for cancers such as ovarian and breast cancer. Another patent, titled "Combination therapy using immunotoxins with interleukin-2," reiterates this approach, emphasizing the potential for augmented anti-tumor activity through this combination therapy.
Career Highlights
Brian Issell has been associated with Cetus Corporation, where he has furthered his research and development efforts. His work at Cetus has allowed him to explore innovative solutions in cancer treatment, contributing to the advancement of medical science.
Collaborations
Issell has collaborated with notable colleagues, including Paul Stevens and L L Houston. These partnerships have likely enriched his research endeavors and fostered a collaborative environment for innovation.
Conclusion
Brian Issell's contributions to immunotoxin research and cancer treatment exemplify the impact of innovative thinking in medicine. His patents reflect a commitment to improving therapeutic options for patients facing challenging diagnoses.